Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
نویسندگان
چکیده
منابع مشابه
Eruptive Lentigines after Adalimumab Therapy
Adalimumab, a TNF-alpha antagonist, is the first fully humanized recombinant immunoglobulin G1 (IgG1) monoclonal antibody. It is presently widely used in the systemic treatment of rheumatoid arthritis, inflammatory bowel disease, moderate and severe psoriasis and hidradenitis suppurativa. However, its administration is associated with a two-fold risk of severe and possibly fatal infections and ...
متن کاملParadoxical Flare of Psoriasis after Ustekinumab Therapy
794 Ann Dermatol Received January 12, 2016, Revised September 24, 2016, Accepted for publication October 24, 2016 Corresponding author: Sik Haw, Department of Dermatology, Inje University Ilsan Paik Hospital, 170 Juhwa-ro, Ilsanseo-gu, Goyang 10380, Korea. Tel: 82-31-910-7224, Fax: 82-31-910-7227, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creati...
متن کاملUstekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
Biologics have revolutionized the therapy of the psoriatic disease spectrum. These new classes of drugs also allow deeper insight into the pathogenesis of the disease and highlight the existence of distinct "molecular" disease subgroups as evidenced by the spectrum of clinical response seen. Molecules associated with both the interleukin (IL)-17 and interferon (IFN)γ pathways have important fun...
متن کاملS100A8/A9 in psoriatic plaques from patients with psoriatic arthritis
OBJECTIVE To evaluate levels of the calcium-binding proteins S100A8 and S100A9 in the skin of patients with psoriatic arthritis. METHODS Skin punch biopsies were obtained from patients with psoriatic arthritis and healthy control subjects. S100A8/A9 were semiquantified via immunohistochemistry and semiquantitative polymerase chain reaction. RESULTS The study included biopsies from nine pati...
متن کاملUstekinumab for the treatment of psoriatic arthritis: an update
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatme...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dermatology Online Journal
سال: 2014
ISSN: 1087-2108
DOI: 10.5070/d3204022338